ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1723

CXCR4-targeted Functionally Selective Immunomodulator Shows Robust Efficacy in Pristane-induced Murine Lupus Model

Annegret Van der Aa1, Simon Tessier1, Jean-Philippe Herbeuval2 and Joël Crouzet1, 1Ermium Therapeutics SAS, Paris, France, 2CBMIT, CNRS UMR 8601, Université Paris Cité, Paris, France

Meeting: ACR Convergence 2022

Keywords: Animal Model, autoimmune diseases, Systemic lupus erythematosus (SLE), Therapy, alternative

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: SLE – Animal Models Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, heterogeneous autoimmune disease. There is still a high unmet need to improve current treatment options. The chemokine receptor CXCR4 has been a target for drug discovery for multiple diseases, mainly focused on antagonists, by blocking the CXCR4 chemokine function. However, data have shown that targeting the minor pocket of the receptor selectively induces an immunomodulating profile through downmodulation of key inflammatory cytokines released by CXCR4 expressing innate immune cells. Furthermore, an upregulated expression of CXCR4 on immune cells is correlating with disease progression in SLE. Therefore, the efficacy of ER145, a CXCR4-targeted functionally selective immunomodulator, was evaluated in the pristane-induced murine lupus model.

Methods: Female Balb/C mice received a single intraperitoneal (i.p.) injection of pristane (0.5mL) to induce disease on Day 1. As of study start, mice were treated once daily for 12 weeks with vehicle (PBS, i.p.), ER145 (3, 10 or 30 mg/kg i.p.) or 15 mg/kg prednisolone orally. As of week 4, levels of anti-dsDNA antibody titers were evaluated every 2 weeks. After 12 weeks of treatment, mice were sacrificed, and cytokine levels were determined in serum using ELISA. Furthermore, kidneys were prepared for histopathological scoring using hematoxylin and eosin (H&E) staining.

Results: Daily treatment of mice for 12 weeks with ER145 did not induce any body weight loss, and none of the animals died. Decreased levels of anti-dsDNA antibodies were observed in all ER145 treatment groups compared to vehicle treated group, as of the first timepoint at week 4. Significant differences were shown as of week 6 for the 30 mg/kg ER145 treatment group and as of week 8 for the 10 mg/kg ER145 treatment group. A dose-response effect was maintained until the end of the study. At week 12, significantly decreased levels of IL-1β, IL-6, IL-17 and TNF-α were measured in serum of mice treated with 30 and 10 mg/kg ER145 compared to vehicle treated mice. In the kidneys, mean glomerulus diameters were slightly reduced in ER145 treatment groups compared to vehicle treated mice, although not statistically significant. Interstitial inflammation was significantly reduced in mice treated with 30 mg/kg (44%), 10 mg/kg (38%), and 3 mg/kg (44%) ER145, compared to the vehicle control group. Summed kidney histopathology scores were reduced in mice treated with ER145 (16-23%) compared to the vehicle treated mice.

Conclusion: ER145, a CXCR4-targeted immunomodulator, has shown robust and dose-dependent efficacy upon once daily i.p. treatment for 12 weeks in pristane-induced lupus mice. Treatment rapidly induced decreased levels of anti-dsDNA antibodies, which were maintained, and decreased levels of key pro-inflammatory cytokines in serum at study end. The suppression of kidney interstitial inflammation with ER145 treatment is convincing and suggests that with time, it would have impacted glomerular pathology and tubular cast formation. Based on these promising pharmacological efficacy data with ER145, orally available CXCR4-targeted immunomodulators are currently being developed as a potentially novel and innovative treatment option for SLE.


Disclosures: A. Van der Aa, Ermium Therapeutics SAS; S. Tessier, Ermium Therapeutics SAS; J. Herbeuval, Ermium Therapeutics SAS; J. Crouzet, Ermium Therapeutics SAS.

To cite this abstract in AMA style:

Van der Aa A, Tessier S, Herbeuval J, Crouzet J. CXCR4-targeted Functionally Selective Immunomodulator Shows Robust Efficacy in Pristane-induced Murine Lupus Model [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/cxcr4-targeted-functionally-selective-immunomodulator-shows-robust-efficacy-in-pristane-induced-murine-lupus-model/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cxcr4-targeted-functionally-selective-immunomodulator-shows-robust-efficacy-in-pristane-induced-murine-lupus-model/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology